Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies - McGregor, Bradley Alexander; Campbell, Matthew T.; Xie, Wanling; Farah, Subrina; Bilen, Mehmet A.; Schmidt, Andrew L.; Sonpavde, Guru P.; Kilbridge, Kerry L.; Choudhury, Atish D.; Mortazavi, Amir; Shah, Amishi Y.; Venkatesan, Aradhana M.; et al. (Cancer, 2021)
Keywords: adrenal tumor; Bladder; bladder or upper tract tumor of variant histology; Confidence intervals; Genital cancers; genitourinary; Histology; Immune checkpoint inhibitors; Immunotherapy; Kidney cancer; Monoclonal antibodies; Oncology; Penis; Platinum; Prednisone; Prostate cancer; rare cancer; Solid tumors; Steroid hormones; Steroids; Targeted cancer therapy; Toxicity; Tumors; Urogenital system; adrenal tumor; genitourinary; rare cancer; bladder or upper tract tumor of variant histology; immunotherapy